ClinicalTrials.gg
TerminatedNCT00384111Updated Jan 14, 2022Results posted

Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)

A Phase 3 interventional study of Zevalin Therapeutic Regimen and R-CVP in Follicular Lymphoma and Lymphoma, Follicular, sponsored by Spectrum Pharmaceuticals, Inc. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-14.

Sponsored by Spectrum Pharmaceuticals, Inc (part of Zydus Lifesciences Limited) · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Study was terminated early as per the Sponsor's decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,187 studies in Lymphoma, Follicular with a site in United States — 128 open to participants now, 217 under way, 20 of them phase 3. Lymphoma, Follicular · United States.

Enrollment
657th of 1,017
26 · median 38
Started
2006
with 37 others
Phase 3
105 of 1,187
9 open now
Registered
401st of 1,187
by date

Among the 1,187 studies in Lymphoma, Follicular with a site in United States, this one is the 657th largest by enrollment of the 1,017 interventional ones that give a count, is one of 38 that started in 2006, is one of 105 in phase 3, and was the 401st registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

128 of the 1,187 studies in Lymphoma, Follicular with a site in United States are open now. Recruiting first, the newest first:

123 more — sign in →

All 128 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,187 studies in Lymphoma, Follicular with a site in United States, or all of them as a file.
02

Study summary

This study will treat follicular lymphoma patients who have not received previous treatment with R-CVP. Half of the patients will receive Zevalin after R-CVP and the other half will receive only R-CVP. The two patient groups will be compared to determine if Zevalin given after R-CVP therapy provides greater benefits than receiving no additional anti-cancer therapy after R-CVP.

03

Conditions studied

  • Follicular Lymphoma
  • Lymphoma, Follicular
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must give written and any authorizations required by local law (e.g., Protected Health Information).
  • Age greater than or equal to 18 years at the time of informed consent.
  • confirmed follicular NHL according to the Revised European American Lymphoma (REAL)/World Health Organization (WHO)classification (from initial diagnosis); grades 1, 2, or 3.
  • Bi-dimensionally (s) in at least one site.
  • High risk NHL as defined by a follicular lymphoma international prognostic index (FLIPI) of 3, 4, or 5 assessed within 3 months prior to randomization.
  • NHL requires treatment as determined by the investigator.
  • Confirmed CD20+ lymphoma cells.
  • (ECOG) performance status of 0, 1,or 2.
  • Expected survival of greater than or equal to 3 months.
  • Male subjects and female subjects of child bearing potential willing to practice effective during the study and willing and able to continue contraception for 1 year after their last dose of study treatment (R CVP for subjects in the observation arm and the Zevalin therapeutic regimen for subjects in the Zevalin arm).

Exclusion criteria

Exclusion Criteria:

  • Previous anticancer treatment for NHL, including chemotherapy, immunotherapy, radiation (locoregional or extended field), radioimmunotherapy, or therapy.
  • Known seropositivity for virus, virus (surface antigen-positive), or other active infection uncontrolled by treatment.
  • Known diagnosis of infection.
  • Presence of primary gastric, central nervous system (CNS), or testicular lymphoma, or transformed lymphoma, or chronic lymphocytic leukemia (CLL).
  • Active therapy within previous 5 years for other , except non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.
  • Abnormal liver function: total >1.5 X (ULN) or >2.5 X ULN.
  • Impairment of renal function (serum creatinine >1.5 X ULN) not due to lymphoma.
  • Concurrent severe and/or uncontrolled medical disease (e.g., uncontrolled diabetes, congestive heart failure, myocardial infarction within 6 months of study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) that could compromise participation in the study.
  • Known to murine and/or chimeric proteins.
  • History of severe allergic or anaphylactic reactions.
  • Known allergy to any components present in rituximab, cyclophosphamide, vincristine, and prednisone (CVP), or Zevalin.
  • Treatment with another study treatment or approved therapy for investigational use within the 12 weeks prior to randomization.
  • Exposure to monoclonal antibodies, cytokines, growth factors, soluble receptors, other recombinant products, or fusion proteins.
  • Females with a positive pregnancy test result at screening or who are currently breastfeeding.
  • Inability to comply with study requirements.
  • Major surgery within 28 days except for diagnosis.
  • In need of immediate intervention to treat life threatening complications.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    1

    Participants will receive standard R-CVP followed by Zevalin Therapeutic Regimen (Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin).

    Drug: Zevalin Therapeutic Regimen · Drug: R-CVP

  • Active comparator
    2

    Participants will receive standard R-CVP.

    Drug: R-CVP

Interventions

  • DrugZevalin Therapeutic Regimen

    Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin

  • DrugR-CVP

    Standard R-CVP

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    Time frame: 18 months

Secondary outcomes

  1. Number of Participants With Serious and Non-serious Adverse Events

    Time frame: 18 months

07

Results

Posted Jan 14, 2022
Limitations and caveats
Outcome measures and safety data were not collected and summarized as the study was terminated early by the sponsor.

Participant flow

Participant flow — Overall Study
MilestoneAll Enrolled Participants
Started26
Completed0
Not completed26
Withdrew: Disease progression3
Withdrew: Adverse event1
Withdrew: Investigator decision3
Withdrew: Study terminated by the sponsor19

Outcome measures

PrimaryNumber of Participants With Adverse Events
Time frame:
18 months

No measurements were reported for this outcome.

SecondaryNumber of Participants With Serious and Non-serious Adverse Events
Time frame:
18 months

No measurements were reported for this outcome.

Adverse events

Collected over Up to end of study (approximately up to 4 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Enrolled Participants———

Baseline characteristics

All participants who were enrolled in the study.

Age, Continuous
Age, Continuous(years)All Enrolled Participants
Mean63 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)All Enrolled Participants
Female9
Male17
08

Study locations

6 sites
  • Integrated Community Oncology Network
    Jacksonville, Florida 32256, United States
  • Gulfcoast Oncology Associates
    Saint Petersburg, Florida 33705, United States
  • Wellstar-Northwest Georgia Oncology Centers
    Marietta, Georgia 30060, United States
  • Oncology Hematology Care Inc.
    Cincinnati, Ohio 45242, United States
  • Chattanooga Oncology Hematology Care
    Chattanooga, Tennessee 37404, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2006 to primary completion in Nov 2008, 25 months.

Results were first posted in Jan 2022, 13 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2006
First posted
Oct 5, 2006
StartActual
Oct 2006
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results first posted
Jan 14, 2022
Last update
Jan 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00384111
Collaborators
CTI BioPharma
Responsible party
Sponsor
First posted
Oct 5, 2006
Start date
Oct 2006
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Jan 14, 2022
Last update
Jan 14, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion